precisionmedicineonline3h
Maze Therapeutics Doses First Patient in Phase II APOL1 Inhibitor Kidney Disease Trial
Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase 2 clinical trial with a novel, potential new medicine that could disrupt current treatment for AKD,” said Harold ...
The Aviationist7h
U.S. Navy Declares Initial Operational Capability for IRST Pods on F/A-18 Super Hornets
The IRST Block II enhances ‘situational awareness by supplementing air-to-air detection and track capabilities, and autonomously or in combination with ...